6月1日，福泰制药盘中下跌3.09%，报433.71美元/股，成交额1.22亿美元。
消息面上，公司宣布美国FDA已正式受理其候选药物Povetacicept治疗IgA肾病的生物制品许可申请（BLA），寻求加速批准路径。加速批准通道是FDA为应对严重疾病且存在未满足医疗需求而设立的机制，Povetacicept若最终获批，有望为IgA肾病患者提供新的治疗选择。尽管该消息标志着药物监管审批进程迈出关键一步，但股价盘中仍出现明显回落。
福泰制药是一家全球性生物技术公司，已开发出针对囊性纤维化、镰状细胞病等病症的获批疗法，并持续推进IgA肾病、1型糖尿病等领域的临床项目。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.